Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.37 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.37 |
| ▸ | KISS1R | Q969F8 | 3/20 | 0.32 |
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | CACNB3 | P54284 | 1/20 | 0.32 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.32 |
| ▸ | PGR | P06401 | 1/20 | 0.32 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.32 |
| ▸ | HTR2B | P41595 | 1/20 | 0.32 |
| ▸ | CACNA2D2 | Q9NY47 | 1/20 | 0.32 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.32 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | ANPEP | P15144 | 3/20 | 0.31 |
| ▸ | LAP3 | P28838 | 2/20 | 0.31 |
| ▸ | MMP1 | P03956 | 2/20 | 0.31 |
| ▸ | MMP3 | P08254 | 2/20 | 0.31 |
| ▸ | MMP9 | P14780 | 2/20 | 0.31 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24119253 | 0.80 | KISS1R (0.31) | KISS1RALDH1A1 | |
| SCHEMBL8462357 | 0.79 | RNPEP (0.37) | RNPEPSLC7A5KISS1RCACNA2D1ALDH1A1 | |
| SCHEMBL18473806 | 0.78 | SLC7A5 (0.38) | SLC7A5SLC1A3SLC1A2 | |
| SCHEMBL5021517 | 0.78 | GABRR1 (0.40) | ALDH1A1 | |
| SCHEMBL17789270 | 0.77 | RNPEP (0.36) | RNPEPSLC7A5KISS1RCACNA2D1ALDH1A1 | |
| SCHEMBL19472111 | 0.77 | RNPEP (0.32) | RNPEPSLC7A5ALDH1A1TDP1 | |
| SCHEMBL16473990 | 0.77 | RNPEP (0.32) | RNPEPSLC7A5ALDH1A1TDP1 | |
| SCHEMBL12074463 | 0.76 | TSHR (0.33) | ALDH1A1 | |
| SCHEMBL1709308 | 0.76 | TSHR (0.33) | ALDH1A1 | |
| SCHEMBL269900 | 0.76 | TSHR (0.33) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230287009-A1 | OXO-SUBSTITUTED COMPOUND | Sumitomo Pharma Co., Ltd. (JP) | 2023-09-14 | — | — | US | disclosed |
| US-11718626-B2 | Macrocyclic compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2023-08-08 | — | — | US | disclosed |
| US-11702431-B2 | Oxo-substituted compound | Sumitomo Pharma Co., Ltd. (JP) | 2023-07-18 | — | — | US | disclosed |
| US-20180222858-A1 | DERIVATIVES OF DOLASTATIN 10 AND AURISTATINS | PIERRE FABRE MEDICAMENT (FR) | 2018-08-09 | — | — | US | disclosed |
| US-20160068566-A1 | DERIVATIVES OF DOLASTATIN 10 AND AURISTATINS | PIERRE FABRE MEDICAMENT (FR) | 2016-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11702431-B2 | Oxo-substituted compound | CYP51A1, OXA1L, O60361 | RNPEP 299/4885SLC7A5 456/4885KISS1R 4559/4885 |
| US-11718626-B2 | Macrocyclic compounds for treatment of medical disorders | CFD, TFPI, CFH | RNPEP 244/4885SLC7A5 907/4885KISS1R 4203/4885 |
| US-20180222858-A1 | DERIVATIVES OF DOLASTATIN 10 AND AURISTATINS | NR1H4, HCAR3, VDR | RNPEP 2038/4885SLC7A5 405/4885KISS1R 433/4885 |
| US-20160068566-A1 | DERIVATIVES OF DOLASTATIN 10 AND AURISTATINS | NR1H4, HCAR3, VDR | RNPEP 2059/4885SLC7A5 404/4885KISS1R 403/4885 |
| US-20230287009-A1 | OXO-SUBSTITUTED COMPOUND | CYP51A1, OXA1L, O60361 | RNPEP 299/4885SLC7A5 456/4885KISS1R 4559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.